Literature DB >> 9224330

A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer.

M J Barry1, F J Fowler, L Bin, J E Oesterling.   

Abstract

PURPOSE: Our aim was to define the spectrum of urological care for benign prostatic hyperplasia (BPH) and clinically localized prostate cancer.
MATERIALS AND METHODS: In 1995 a random sample of 394 American urologists was surveyed with a response rate of 67%.
RESULTS: Respondents reported seeing a median of 240 BPH patients during the preceding 12 months, and they had prescribed alpha-blockers for 70 and finasteride for 15. They had performed a median of 25 transurethral prostatectomies but few other operations for BPH. Almost all urologists routinely used digital rectal examinations and prostate specific antigen tests for BPH diagnosis. The next most common studies were American Urological Association symptom scores and uroflowmetry. Pressure-flow studies were rarely done. Respondents reported seeing a median of 35 new patients with prostate cancer during the last year, and performing a median of 90 prostate biopsies and 13 radical prostatectomies. Respondents had referred a median of 10 patients for external beam radiotherapy but few patients received brachytherapy or cryotherapy. Urologist staging practices varied considerably.
CONCLUSIONS: These data provide a picture of current practice regarding the management of BPH and prostate cancer.

Entities:  

Mesh:

Year:  1997        PMID: 9224330     DOI: 10.1016/s0022-5347(01)64510-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.

Authors:  David A Taub; John T Wei
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

2.  Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians.

Authors:  M M Collins; M J Barry; L Bin; R G Roberts; J E Oesterling; F J Fowler
Journal:  J Gen Intern Med       Date:  1997-04       Impact factor: 5.128

3.  Korean urologist's view of practice patterns in diagnosis and management of benign prostatic hyperplasia: a nationwide survey.

Authors:  Cheol Young Oh; Seung Hwan Lee; Se Jeong Yoo; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

4.  Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.

Authors:  Lalji K Gediya; Aashvini Belosay; Aakanksha Khandelwal; Puranik Purushottamachar; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-12-08       Impact factor: 3.641

5.  Changing patterns of surgical care in the United States, 1980-1995.

Authors:  L J Kozak; E McCarthy; R Pokras
Journal:  Health Care Financ Rev       Date:  1999

Review 6.  Doxazosin in the treatment of benign prostatic hypertrophy: an update.

Authors:  Timothy J Wilt; Roderick MacDonald
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

7.  Risk factors for incident delirium among urological patients: a systematic review and meta-analysis with GRADE summary of findings.

Authors:  L Sanyaolu; A F M Scholz; I Mayo; J Coode-Bate; C Oldroyd; B Carter; T Quinn; J Hewitt
Journal:  BMC Urol       Date:  2020-10-27       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.